Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
Recruiting
Observational Study
Prostate Cancer
Adaptive Radiotherapy
Quality of Life
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 120
- Sex
- Male
- Study type
- Observational
- Participants needed
- 150 (estimated)
- Sponsor
- Jena University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital pati…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* no androgen deprivation therapy within the last 2 months prior to RT
* good performance status (Eastern Cooperative Oncology Group, ECOG, 0/1)
* no secondary malignancy
Contacts